Apr 19, 2022
Dr. Stephen Quake, President of the Chan Zuckerberg Biohub Network, spoke to CANCER BUZZ about the application of liquid biopsies across multiple cancer stages and their potential to improve patient outcomes, minimize financial toxicity, and create health equity through greater testing access and lower cost. He identified trends that are shaping the future of cancer research, including the amazing developments in new cancer screens for diseases where they don't currently exist. Hear about the hydroxymethylation measurement techniques pioneered by his lab, which is the exact science now being used by many investigational multi-cancer early detection (MCED) assays to screen for cancers which don’t have guideline-approved tests, like pancreatic and ovarian cancer.
Guest:
Stephen Quake, PhD
Professor of Bioengineering and Applied Physics, Stanford University
Co-President, Chan Zuckerberg Biohub Network
Resources: